HONG KONG - Mumbai-based Glenmark Pharmaceuticals Ltd. has been granted manufacturing and marketing approval for the launch of its antiviral drug, favipiravir, for the treatment of mild to moderate COVID-19, a move it deems a “landmark development for COVID-19 patients in India.” Read More

BEIJING – Suzhou, China-based Ascentage Pharma Group Inc. said on June 22 that it is working with Astrazeneca plc’s hematology R&D unit, Acerta Pharma, to develop a combination therapy of its Bcl-2 inhibitor, APG-2575, with Acerta's BTK inhibitor, Calquence (acalabrutinib). The first patient has been dosed in the U.S. Read More

HONG KONG – South Korea-based Genexine Inc. has started enrolling a phase I/II trial for a DNA vaccine targeting COVID-19 called GX-19. Read More

BEIJING – Chinese state-backed vaccine developer China National Biotec Group (CNBG), of Beijing, said on June 16 that its inactivated COVID-19 vaccine candidate produced a seroconversion rate of up to 100% in a phase I/II trial that enrolled 1,120 healthy subjects. Read More

Nan Fung Life Sciences is “looking to make a significant presence in the field,” said Engrail Therapeutics Inc. CEO Vikram Sudarsan, whose firm bagged a $32 million series A round led by the global investment platform of Hong Kong’s Nan Fung Group, and its support represents “a clear statement in that direction.” Read More

Countries and health care providers should hope for the best but prepare for the worst as a resurgence of COVID-19 is expected in the fall, just as the influenza season hits. Read More

By targeting chimeric antigen receptors (CARs) to a senescence marker, researchers at Memorial Sloan-Kettering Cancer Center have developed a CAR T cell that had beneficial effects in mouse models of both liver fibrosis and lung cancer. Read More

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Acadia, Aribio, Ascentage, Ascletis, Biosig Technologies, Clover, Eli Lilly, Evelo, Evgen, FSD, Hua Medicine, Humanigen, Inflarx, Innovent, Kiniksa, Neuren, Remegen, Ridgeback, Sagimet. Read More

Data presented at the American Association for Cancer Research. Read More

Biopharmas in Asia-Pacific raising money in public or private financings, including: Corat, Greenlight, Yumab. Read More

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Achilles Vaccines, Adamis, Agenus, Amarin, Amyndas, Apotex, Armata, Astrazeneca, Atyr, Avacta, Berg, Betta, Cascade Chemistry, Cellics, Cobra, Codagenix, Dr. Reddy’s, Farmacore, G1, Gelesis, Genor, Hikma, Immunoprecise Antibodies, Immuron, Innovation, Kalytera, Kamada, Kedrion, Lead Discovery Center, Leidos, Litevax, Matrix Biomed, Merck, Moleculin, Monopar, Nascent , Northstar Medical Radioisotopes, Olix, Oncolys, Orgenesis, PDS, Quartesian, Qurient, Renibus, Salzman, Staidson, Synairgen, Teva, Themis, Therapeutic Solutions, Tonix, Transcelerate, Treos. Read More

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Aclaris, Ampio, Arch, Ascentage, Beigene, Bio-Thera, Curevac, Cynata, Edesa, Kyowa Kirin, Innovent, Kamada, Merck, Pear, PTC, Sanofi, Regeneron, Ultragenyx. Read More

The latest global regulatory news, changes and updates affecting biopharma, including: Auromedics, Bring Entrepreneurial Advancements to Consumers Here In North America, Central Drugs Standard Control Organisation, FDA, Gilead Sciences, Medicines and Healthcare products Regulatory Agency, NIH, Pharmaceutical and Medical Devices Agency, Somerset, Therapeutic Goods Administration, U.S. Patent and Trademark Office. Read More